Payors and Employers

With kidney stone cases increasing by 2% a year1, we seek to partner to offer a quality patient experience, while generating cost savings for payors and self-insured employers.

# 0
MOST EXPENSIVE CAUSE OF ED VISITS

As compared to the top 10 most common outpatient conditions presented at ED2

0 %
REPEAT ED VISITS
1 in 9 patients experience repeat ED visits post-treatment3
0 %
HIGHER COST
Repeat ED visits cost 80% more than one-off visits4
0 M
LOST WORKDAYS
with indirect costs totaling $775M5

Integrated Urology Platform for Better Outcomes

Powered by Dornier MedTech, our integrated urology platform is uniquely designed to help patients get the timely treatment that they need, and aims to contribute to a lower risk of recurrence thereafter. Our full suite of offerings extends from our patient-centric WPE Wellness program to clinical services and best-in-class medical devices and consumables; covering the full spectrum of education, prevention, treatment, and
post-treatment care.

By helping patients manage their lifestyle and condition, we look to generate cost savings and create a seamless healthcare experience for lives covered that payors and employers can be proud of. Reach out to us to be a part of our beta launch.

  1. Hill, A. J., Basourakos, S. P., Lewicki, P., Wu, X., Arenas-Gallo, C., Chuang, D., Bodner, D., Jaeger, I., Nevo, A., Zell, M., Markt, S. C., Eisner, B. H., & Shoag, J. E. (2022). Incidence of kidney stones in the United States: The Continuous National Health and Nutrition Examination Survey. Journal of Urology, 207(4), 851–856. https://doi.org/10.1097/ju.0000000000002331
  2. Caldwell, N., Srebotnjak, T., Wang, T., & Hsia, R. (2013). “How Much Will I Get Charged for This?” Patient Charges for Top Ten Diagnoses in the Emergency Department. PLoS ONE, 8(2).https://doi.org/10.1371/journal.pone.0055491
  3. *Within 30 days for treatment of kidney stone. Scales, C. D., Lin, L., Saigal, C. S., Bennett, C. J., Ponce, N. A., Mangione, C. M., & Litwin, M. S. (2015). Emergency department revisits for patients with kidney stones in California. Academic Emergency Medicine, 22(4), 468–474. https://doi.org/10.1111/acem.12632
  4. *Assuming URS, with relative cost savings assumptions developed. McClintock, T. R., Friedlander, D. F., Feng, A. Y., Shah, M. A., Pallin, D. J., Chang, S. L., Bader, A. M., Feeley, T. W., Kaplan, R. S., & Haleblian, G. E. (2021). Determining variable costs in the acute urolithiasis cycle of care through time-driven activity-based costing. Urology, 157, 107–113. https://doi.org/10.1016/j.urology.2021.05.102
  5. Saigal, C. S., Joyce, G., Timilsina, A. R., & the Urologic Diseases in America Project. (2005). Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management? Kidney International, 68(4), 1808–1814. https://doi.org/10.1111/j.1523-1755.2005.00599.x